// App-Quantinova.ai

: In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Researchers

Presenter

  • Ehsan Bahrami

Principal Investigators

  • Jan Philipp Schmid

  • Martin Becker

  • Anna-Katharina Wirth

  • Rupert Ollinger

  • Roland Rad

  • Binje Vick

  • Ashok Kumar Jayavelu

  • Matthias Mann

  • Tobias Herold

  • Irmela Jeremias

Medical Centers

  • Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technische Universität München, Munich, Germany

  • German Cancer Consortium (DKTK), Munich, Germany

  • German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany

  • German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Department of Pediatrics, Dr. von Hauner Childrens Hospital, Ludwig Maximilian University, Munich, Germany

  • Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Munich, Germany

  • Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany

  • Institute of Molecular Oncology and Functional Genomics, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

  • Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital, Munich, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Alzheimer's disease

  • Acute Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • C-X-C motif chemokine receptor 4

  • Cluster of Differentiation 29

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved